Cepheid, a California-based molecular diagnostics company, and the Foundation for Innovative New Diagnostics (FIND) announced a new collaboration to accelerate the development of a rapid HIV viral load test. This viral load test will run on the platform of Cepheid’s GeneXpert, the ground-breaking rapid test to diagnose drug-susceptible and drug-resistant tuberculosis. Given the high rates of TB/HIV co-infection, especially in southern Africa, a diagnostic with both these capabilities could be incredibly beneficial in diagnosing and managing these two deadly infectious diseases. To read the full press announcement, click here.
The Honorable Professor Nkandu Luo, now Zambia’s Minister of Gender and Child Development, is a physician, professor of microbiology and immunology, a former Parliament member, former […]
In a continuation of World TB Day coverage, the following guest post from study authors Martha Priedeman Skiles and Stephanie Mullen tells how current data from […]
Overtaken by microbicide trial results, USAID update on global health research raises questions of HIV prevention pipeline In one corner of room 121 at the Canon […]
Antibiotic-resistant bacteria prompts “National Action Plan,” with global strategies targeting pathogens that include multidrug-resistant tuberculosis
“Antibiotic resistance is a global health problem that requires international attention and collaboration because bacteria do not recognize borders” National Action Plan for Combating Antibiotic-Resistant Bacteria […]